3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
4
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pinealoma
1
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Interventions
Cisplatin
15
pembrolizumab
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Carboplatin
10
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Paclitaxel
7
durvalumab
6
Radiotherapy, Intensity-Modulated
6
Cetuximab
6
cemiplimab
5
Radiotherapy
5
Radiation
5
Pemetrexed
5
Nivolumab
5
Biopsy
5
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
atezolizumab
3
Taxes
3
Oxaliplatin
3
Docetaxel
3
ipatasertib
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Immunotherapy
×
90 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled